BEIJING — China’s drug authority has approved for clinical trials an inhaled Covid-19 vaccine co-developed by domestic firm CanSino Biologics, the company said in a filing on Tuesday.
The move comes after the National Medical Products Administration gave another CanSino vaccine conditional approval last month, allowing it for public use.
China currently has five coronavirus vaccines that have been given conditional market approval or allowed for emergency use, but none of these are administered by inhalation.
CanSino said in its latest filing on the Hong Kong stock exchange that the vaccine for inhalation was jointly developed by the company and the Beijing Institute of Biotec…
Keep on reading: China approves inhaled CanSino vaccine for clinical trials